Ibrexafungerp and Caspofungin: Efficacy Against Drug-Resista
2026-05-03
Wiederhold et al. demonstrate that ibrexafungerp, a novel triterpenoid, exhibits potent in vitro and in vivo efficacy against fluconazole-resistant Candida auris, even with delayed therapy initiation. These findings reinforce the therapeutic relevance of β-(1,3)-D-glucan biosynthesis inhibition and inform the development and benchmarking of antifungal agents, including established lipopeptide drugs like caspofungin.
Nuclear cGAS Limits L1 Retrotransposition via CHK2-TRIM41 Ax
2026-05-02
This study reveals that nuclear cGAS suppresses LINE-1 retrotransposition by facilitating TRIM41-mediated ubiquitination and degradation of ORF2p, a process that is regulated by CHK2-dependent phosphorylation. These findings provide new insight into the posttranslational control of genome stability and highlight a molecular intersection relevant to DNA damage response and cancer research.
CB-5083: Translating p97 Inhibition into Oncology Breakthrou
2026-05-02
This article explores the mechanistic underpinnings and translational trajectory of CB-5083, a potent, selective, and orally bioavailable p97 inhibitor. We connect new insights into endoplasmic reticulum (ER) protein/lipid homeostasis with the strategic use of CB-5083 in preclinical and translational oncology research, providing both evidence-backed protocol guidance and a forward-looking agenda for therapeutic discovery.
HyperScribe™ T7 High Yield RNA Synthesis Kit: Evidence & Wor
2026-05-01
The HyperScribe™ T7 High Yield RNA Synthesis Kit enables robust in vitro transcription using T7 RNA polymerase, delivering up to 50 μg RNA per 20 μL reaction under standard conditions. Its design supports diverse applications, including capped and biotinylated RNA production for research workflows.
Thiothixene: Bridging Dopamine Antagonism & Immune Modulatio
2026-04-30
This thought-leadership article unpacks the dual mechanistic roles of Thiothixene, a typical antipsychotic agent, in both neuropharmacology and immunological research. Emphasizing translational value, it maps recent advances in schizophrenia genetics to actionable experimental strategies—advocating for Thiothixene as a uniquely versatile tool. Drawing on peer-reviewed evidence and showcasing APExBIO's product intelligence, it offers an integrated perspective for researchers seeking next-generation therapies and robust cell-based assay design.
Lipid Scrambling, Ferroptosis, and Tumor Immunity: Mechanist
2026-04-30
Yang et al. identify TMEM16F-mediated lipid scrambling as a critical suppressor of ferroptosis at the plasma membrane, revealing how its inhibition sensitizes tumor cells to ferroptotic death and enhances immune rejection. These findings provide mechanistic insight into the interplay between membrane lipid dynamics, cell death, and immunotherapy, informing future research on redox biology and membrane-targeted interventions.
mCherry mRNA: Optimizing Red Fluorescent Protein Assays
2026-04-29
EZ Cap™ mCherry mRNA (5mCTP, ψUTP) sets a new standard for immune-evasive, robust fluorescent protein expression in cell biology. Discover workflow enhancements, troubleshooting strategies, and experimental insights that unlock reproducible reporter gene mRNA performance.
Inducing Embryonic Dormancy via mTOR Inhibition: Protocol Ad
2026-04-29
This article reviews the protocol developed by Iyer et al. for inducing a reversible, diapause-like dormant state in mammalian early embryonic cells through mTOR inhibition. The approach offers a noninvasive, scalable alternative to traditional in vivo methods, with broad implications for developmental biology and reproductive technology.
Toremifene Citrate: Applied Workflows in Estrogen Receptor R
2026-04-28
Toremifene Citrate stands out as a robust oral selective estrogen receptor modulator, enabling reproducible, high-fidelity estrogen receptor signaling studies. This guide delivers protocol-driven insights, troubleshooting tips, and practical workflow enhancements to help researchers maximize assay success using Toremifene Citrate from APExBIO.
Synthetic Cleavage-Resistant TREM2 Enhances Macrophage Effer
2026-04-28
Dong et al. engineered a synthetic, cleavage-resistant TREM2 (CRT) receptor that sustains efferocytosis in inflammatory environments by resisting ADAM17-mediated shedding. Their macrophage-selective mRNA delivery approach led to in situ generation of CRT-expressing macrophages, reducing inflammation in mouse models of steatohepatitis and atherosclerosis.
Exemestane in Translational Breast Cancer Research: Mechanis
2026-04-27
Explore how Exemestane, a steroidal aromatase inhibitor, advances translational breast cancer research. This article provides in-depth analysis of its mechanism, protocol optimization, and practical assay guidance not found elsewhere.
Scenario-Driven Solutions in Antibacterial Assays with Gepot
2026-04-27
This article delivers evidence-based, scenario-driven insights for researchers performing cell viability, proliferation, and cytotoxicity assays using Gepotidacin (SKU BA1220). By addressing common laboratory challenges with quantitative data and validated protocols, the guide demonstrates how Gepotidacin enables reproducible, sensitive, and robust antibacterial research. Practical decision-making, protocol optimization, and vendor selection are all anchored to the unique properties of Gepotidacin.
E-4031 in 3D Cardiac Electrophysiology: Mechanisms & Strateg
2026-04-26
Explore how E-4031, a benchmark hERG potassium channel blocker, is shaping the future of cardiac electrophysiology research. This thought-leadership article blends mechanistic depth with guidance for translational scientists, highlighting advances in 3D cardiac organoid modeling and high-content proarrhythmic risk assessment. Supported by recent innovations in shell microelectrode arrays and robust evidence, it provides a strategic roadmap for leveraging E-4031 in next-generation translational workflows.
SMAD3 Inhibition Reduces ADAMTS-5 in Early Osteoarthritis Mo
2026-04-25
Xiang et al. provide mechanistic evidence that inhibiting SMAD3 upregulates miRNA-140, which in turn downregulates ADAMTS-5 expression in early osteoarthritis (OA). These findings advance understanding of cartilage degeneration and suggest new molecular targets for early OA intervention.
Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO): Pract
2026-04-24
The Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO) is formulated to prevent protein degradation during extraction and assay workflows without interfering with cation-dependent processes. It is best used in workflows such as Western blotting, co-immunoprecipitation, and kinase assays where broad-spectrum protease inhibition and EDTA exclusion are required. It should not be used in protocols that specifically require EDTA-mediated inhibition or where DMSO is incompatible.
459 records 20/31 page Previous Next First page 上5页 1617181920 下5页 Last page